Passive immunotherapies, mainly represented by monoclonal antibodies, are efficacious in many types of cancers, and the first used in clinical practice were EGFR- or VEGF-antibodies in colorectal cancer, and trastuzumab in Her-2-positive breast cancer. Here, ERBB2 is linked to breast cancer.